Navigation Links
Sangamo BioSciences Announces Presentation of Clinical Data Demonstrating Functional Control of Viremia in HIV-Infected Subjects Treated with SB-728-T
Date:9/12/2013

are generally not susceptible to the most common strain of HIV.

Summary of Clinical Trial Design
About SB-728-902 Cohorts 1-3
The study is an open-label Phase 1 clinical trial to evaluate the safety and tolerability of single infusions of an escalating dose of an autologous (a patient's own) CD4+ T-cell product genetically modified at the CCR5 gene by CCR5-specific ZFNs (SB-728-T). The trial enrolled nine HIV-infected subjects (three cohorts of three subjects each) who have sub-optimal T-cell levels and no detectable viral load on long-term ART.  Subjects remained on their existing antiviral therapy while receiving treatment with SB-728-T.

About SB-728-902 Cohort 5
Up to 20 HIV-infected subjects heterozygous for the CCR5 delta-32 mutation (i.e. with one CCR5 gene that is naturally modified) who are currently on ART are being enrolled and will receive a single intravenous infusion of SB-728-T (5 to 30 billion modified cells). Two months after SB-728-T treatment, subjects undergo a 16 week TI during which time their ART is discontinued. ART will be reinstituted in subjects whose CD4 T-cell counts drop to <350 cells/ mm3 and/or whose HIV-RNA increases to >100,000 /mL for three consecutive weekly measurements. At the end of the TI, subjects with a sustained detectable HIV viral load are reinstituted on ART. Subjects with an undetectable viral load can remain off ART until HIV RNA levels are detectable or their CD4 T-cell count drops below 350 cell/mm3 for three consecutive weekly measurements.

A total of ten subjects have been treated in this cohort. 

Of the six evaluable subjects, we observed two subjects in which their VL became undetectable during TI from ART:

  • In one subject, VL suppression at, or below, the limit of quantification (LOQ) of virus was sustained from week 11 – 19 of TI and the TI is ongoing.
  • In the s
    '/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sangamo BioSciences to Acquire Ceregene
2. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
3. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
4. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
5. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
6. Sangamo BioSciences Reports First Quarter 2013 Financial Results
7. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
8. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
9. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
10. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
11. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  EnteroMedics Inc. (NASDAQ: ETRM ), the ... obesity, metabolic diseases and other gastrointestinal disorders, today announced ... August 7, 2014 at 11:00 AM Eastern Time to ... 30, 2014 and to provide a business update. ... conference call may be accessed by dialing (877) 280-7473 ...
(Date:7/29/2014)... 29, 2014 New high priced hepatitis C ... by a projected $2.9 to $5.8 billion next year, ... Milliman released today by the Pharmaceutical Care Management Association ... increase by as much as 8.6 percent in 2015 ... Sovaldi and Olysio. The study finds that ...
(Date:7/29/2014)... and NEW YORK , ... of the executive management team of Caremark Rx, ... Media ( www.pbm365.com ).  PBM365 is the leading independent ... reporting, insight, analysis and opinion on the pharmacy ... will provide insightful and timely coverage of, and context ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Drew Crawford Announces Launch of PBM365 Media 2
... Test builds on company,s suite of tests to ... Laboratories, a leading clinical-diagnostics and biomedical-research laboratory specializing ... new diagnostic assay designed to help physicians better ... infections. The company will introduce the Pneumococcal ...
... of Fast-Tracked Antiplatelet Agent Showed No Increase in TIMI ... Given With Standard Platelet TherapyKENILWORTH, N.J., March 12 ... ) Phase II trial of SCH 530348, a novel ... The Lancet and demonstrated that the investigational ...
Cached Medicine Technology:IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 4Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 5Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 6Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 7
(Date:7/29/2014)... Regardless of the good things that happen in ... those with. Love is about understanding, commitment and sharing ... also about overcoming all the challenges that a relationship ... women need to know how to understand guys. ... please visit the official website at http://www.dailygossip.org/enchant-him-review-7111 . ...
(Date:7/29/2014)... Daily Gossip indicates in its Acne No More ... beautiful and clear skin in just 30 to 60 days. ... results even sooner than that. The new method was created ... step by step program, too. , Mike Walden claimed ... battled this condition for a decade and none of the ...
(Date:7/29/2014)... (HealthDay News) --,The time at which heart attack patients ... survival, new research suggests. Showing up at the ... is associated with a 13 percent higher risk for ... Every year, more than 250,000 people suffer a ... heart attack, which is caused by a complete blockage ...
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells ... safety and effectiveness, according to a review in the ... , the official medical journal of the ... cells offer tremendous potential, but the marketplace is saturated ... patients at risk," write Dr Michael T. Longaker of ...
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Chlorine helps keep pool ... likely to develop eye infections, doctors say. ... well as blurry vision, said Dr. Sampson Davis, an ... New Jersey. It,s important to understand why this ... away the outer film layer of the eye that ...
Breaking Medicine News(10 mins):Health News:How to Reach the Heart of the Perfect Guy with "Enchant Him Program" - a Report by Daily Gossip Magazine 2Health News:Acne No More Review Reveals Most Effective Acne Cure Program 2Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2Health News:Protect Your Eyes When Hitting the Pool 2
... serious complications, researchers say , THURSDAY, Oct. 22 (HealthDay ... scans are better than standard X-rays at detecting the ... known as swine flu. , Researchers examined seven patients ... all of them. Three of the patients also received ...
... social interaction, researchers say , WEDNESDAY, Oct. 21 (HealthDay ... with autism has been identified by U.S. researchers, who ... diagnose and treat the disorder. , This genetic signature ... to the way that genes are switched on and ...
... to new treatments , WEDNESDAY, Oct. 21 (HealthDay News) ... that the gene behind Gaucher disease, a rare neurological ... those of us who work with rare disorders, it ... applicable to more common disorders," said Dr. Ellen Sidransky, ...
... women have tougher time shedding those excess pounds, study finds ... gain more than 15 pounds during pregnancy tend to retain ... finds. , Oregon researchers collected data on almost 1,700 obese ... gave birth between 2000 and 2005. , "We found that ...
... plans to rethink testing for breast, prostate tumors, contrary ... -- The American Cancer Society says it is not ... widely reported Wednesday. , "We are not redoing or ... going to restate our guidelines to emphasize the inadequacies ...
... Ohio It was once thought that the two communities ... cells and the normal cells that surround them existed ... cells encouraged cells within the tumor to become malignant, but ... new study led by Ohio State University cancer researchers published ...
Cached Medicine News:Health News:Less Sensitivity to Hormone May Play Role in Autism 2Health News:Gene Behind Gaucher Disease a Player in Parkinson's 2Health News:Gene Behind Gaucher Disease a Player in Parkinson's 3Health News:For Obese, Weight Gained in Pregnancy May Not Leave 2Health News:For Obese, Weight Gained in Pregnancy May Not Leave 3Health News:American Cancer Society Stands By Cancer Screening Guidelines 2Health News:American Cancer Society Stands By Cancer Screening Guidelines 3Health News:American Cancer Society Stands By Cancer Screening Guidelines 4Health News:Study shows how normal cells influence tumor growth 2
Provides quick freezing and quick defrosting. Lightweight probe tips have high conductivity silver. Useful for Cataract, Retinal Detachment, Glaucoma and Intra-vitreal surgery. Includes either one ca...
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
... planned ECCE with peristaltic pump with ... suction, reflux possible with multi-function footswitch ... all critical functions. You can also ... actual vacuum level indicated by Bar ...
Medicine Products: